NOTE: This disposition is nonprecedential.

 

United States Court of Appeals 

for the Federal Circuit ______________________ 

JAY P. GINSBERG,

Petitioner

v.

DEPARTMENT OF VETERANS AFFAIRS,

Respondent

______________________ 

2022-1900

______________________ 

Petition for review of the Merit Systems Protection 

Board in No. AT-1221-21-0116-W-1.

______________________ 

Decided: October 31, 2023

______________________ 

SHANNON POLVI, Cromer Babb Porter Hicks, LLC, Columbia, SC, argued for petitioner. 

 LIRIDONA SINANI, Commercial Litigation Branch, Civil 

Division, United States Department of Justice, Washington, DC, argued for respondent. Also represented by BRIAN 

M. BOYNTON, ELIZABETH MARIE HOSFORD, PATRICIA M.

MCCARTHY. 

 ______________________ 

Before STOLL, CUNNINGHAM, and STARK, Circuit Judges.

Case: 22-1900 Document: 46 Page: 1 Filed: 10/31/2023
2 GINSBERG v. DVA

STOLL, Circuit Judge. 

Dr. Jay P. Ginsberg appeals the decision of the Merit 

Systems Protection Board affirming the Department of 

Veterans Affairs’ personnel actions related to his Research 

Health Scientist position. Because substantial evidence 

supports the Board’s finding, we affirm.

BACKGROUND

Dr. Ginsberg began his employment with the Department of Veterans Affairs (VA) in the Research Department 

of the Dorn VA Medical Center as a Psychologist in 

March 2004 with a term appointment of two years. His title was corrected to Research Health Scientist and his appointment was extended multiple times until his last 

appointment, which had a Not To Exceed (NTE) date of December 2019. During Dr. Ginsberg’s last appointment, he 

was working on a research project that was initially 

awarded to him and Dr. James Burch, with both being 

named as Co-Principal Investigators.

Concurrently, in March 2009, Dr. Ginsberg was appointed to a Clinical Psychologist-Neuropsychologist position in the Transition and Care Management Service at the 

Dorn VA Medical Center. In 2018, Dr. Ginsberg’s clinical 

privileges were suspended. In May 2019, the VA removed 

Dr. Ginsberg from his clinical position for (1) failure to enter patient progress notes into the Computerized Patient 

Reporting System and (2) failure to perform acceptable 

standard of practice. Dr. Ginsberg appealed his removal to 

the Merit Systems Protection Board, asserting that (1) he 

had regularly made protected disclosures and complaints 

to the VA regarding issues with the credentialing and performance review standards and the reporting system; and 

(2) his removal was retaliation for his protected disclosures. The Board denied Dr. Ginsberg’s request for corrective action. Ginsberg v. Dep’t of Veterans Affs., No. AT1221-19-0529-W-1, 2020 WL 1508133 (M.S.P.B. Mar. 23, 

2020). On appeal, we affirmed the Board’s decision. 

Case: 22-1900 Document: 46 Page: 2 Filed: 10/31/2023
GINSBERG v. DVA 3

Ginsberg v. Dep’t of Veterans Affs., 844 F. App’x 365 

(Fed. Cir. 2021).

The loss of Dr. Ginsberg’s clinical privileges, however, 

triggered a sequence of events relating to his research position. At this time, Dr. Ginsberg was working on a research project that was awarded to him and Dr. James 

Burch, with both being named as Co-Principal Investigators. Dr. David Omura, Director of the Dorn VA Medical 

Center, notified Dr. Kathlyn Haddock, Associate Chief of 

Staff who oversaw Dr. Ginsberg’s research work, that 

Dr. Ginsberg’s clinical privileges had been suspended. 

Dr. Haddock then notified the Dorn VA Medical Center Institutional Review Board (IRB) of this change. In August

2018, the IRB voted to recommend changing the scope of 

Dr. Ginsberg’s role to prevent him from accessing patient 

and subject data. Subsequently, in November 2019, 

Dr. Ginsberg’s title on the project was changed from CoPrincipal Investigator to Co-Investigator, and his name 

was removed from the research grant.

In October 2019, Dr. Ginsberg requested bridge funding for his research project for six months after December 31, 2019, his NTE date. Bridge funding is a six-month

extension of salary following a project’s end date that allows the project leaders to complete pending research 

items. Dr. Haddock contacted the Office of Research and 

Development (ORD) inquiring whether Dr. Ginsberg was 

eligible for such funding and was notified that Dr. Ginsberg was ineligible under the ORD Program Guide 

1200.15, because such funding was only awarded to principal investigators who held at least a 5/8ths appointment,1

which Dr. Ginsberg no longer held after being removed 

1 VA appointments are represented in eighths, 

where each eighth represents five hours per week. Accordingly, 5/8ths represents a VA appointment of 25 hours per 

week.

Case: 22-1900 Document: 46 Page: 3 Filed: 10/31/2023
4 GINSBERG v. DVA

from his clinical position. Dr. Ginsberg’s appointment as a 

Research Health Scientist ended on his NTE date of December 31, 2019.

Dr. Ginsberg filed an individual right of action (IRA) 

appeal to the Board under the Whistleblower Protection 

Act, asserting that the agency retaliated against him for 

(1) disclosing that the agency’s credentialing and performance review standards for its clinical practice were improper; (2) filing a complaint with the Office of Special 

Counsel regarding removal from his Clinical Psychologist 

position; and (3) appealing to the Board, challenging the 

removal from his Clinical Psychologist position. He asserted that the agency’s retaliation consisted of (1) denying 

his bridge funding request; (2) demoting him from Co-Principal Investigator to Co-Investigator; (3) excluding him 

from participation in new VA funded research; (4) removing his name from the research grant; and (5) ending his 

appointment on December 31, 2019. 

The Board found that Dr. Ginsberg had established a 

prima facie case of whistleblower reprisal, but that the VA 

demonstrated by clear and convincing evidence that it 

would have taken the same actions against Dr. Ginsberg

even in the absence of his protected disclosures and activity. Ginsberg v. Dep’t of Veterans Affs., No. AT-1221-21-

0116-W-1, 2022 WL 1144886, at *1 (M.S.P.B. Apr. 15, 

2022) (Board Decision).

Dr. Ginsberg appeals. We have jurisdiction under 

28 U.S.C. § 1295(a)(9).

DISCUSSION

Our review of Board decisions is limited by statute. We 

uphold the Board’s decision unless it is “(1) arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law; (2) obtained without procedures required by 

law, rule, or regulation having been followed; or (3) unsupported by substantial evidence.” 5 U.S.C. § 7703(c). 

Case: 22-1900 Document: 46 Page: 4 Filed: 10/31/2023
GINSBERG v. DVA 5

Substantial evidence is “such relevant evidence as a reasonable mind might accept as adequate to support a conclusion.” Shapiro v. Social Sec. Admin., 800 F.3d 1332, 

1336 (Fed. Cir. 2015) (internal quotation marks and citation omitted). 

We conclude that substantial evidence supports the 

Board’s finding that the government demonstrated that 

the VA would have taken the same actions absent Dr. Ginsberg’s disclosures. The government argues that the 

agency’s actions were a reasonable consequence recommended by the IRB and the ORD given the loss of Dr. Ginsberg’s clinical position and corresponding reduction in 

hours. Dr. Ginsberg responds that the IRB recommendation and the ORD guidance were not mandatory. But the 

issue is whether a reasonable fact finder could find that the 

agency would have taken the same action—adhere to the 

IRB recommendation and the ORD guidance—absent the 

disclosures. See Hathaway v. Merit Sys. Prot. Bd., 

981 F.2d 1237, 1242 (Fed. Cir. 1992) (“We may not upset 

the Board’s reasonable choices so long as they are supported by substantial evidence.”). The recommendation of 

the IRB, even if not mandatory, provides strong evidence 

demonstrating that the agency’s actions would have been 

taken even in the absence of whistleblower action, particularly as “[t]here is no indication that the IRB committee 

members . . . were aware of [Dr. Ginsberg’s] protected disclosures or of his protected activity.” Ginsberg v. Dep’t of 

Veterans Affs., No. AT-1221-21-0116-W-1, 2021 WL 

2894670 (M.S.P.B. July 6, 2021) (Initial Board Decision); 

J.A. 1224–25. Likewise, the existence of a written policy 

supporting the agency’s action is further evidence that the 

agency would have taken the same actions absent the whistleblower activity.

In assessing whether the VA would have taken these 

actions in the absence of Dr. Ginsberg’s protected disclosures and activity, the Board considered the three non-exclusive Carr factors: (1) the strength of the agency’s

Case: 22-1900 Document: 46 Page: 5 Filed: 10/31/2023
6 GINSBERG v. DVA

evidence in support of its action; (2) the existence and 

strength of any motive to retaliate on the part of the 

agency’s officials who were involved in the decision; and 

(3) any evidence that the agency takes similar action 

against employees who did not engage in protected activity 

but who are otherwise similarly situated. Board Decision, 

2022 WL 1144886, at *1–2 (citing Carr v. Soc. Sec. Admin., 

185 F.3d 1318, 1323 (Fed. Cir. 1999)). On appeal, Dr. Ginsberg challenges factual findings made by the Board related 

to each Carr factor. We find substantial evidence supports 

the Board’s finding on all three factors.

As to the first Carr factor, substantial evidence supports the Board’s finding that the “agency’s evidence in 

support of the personnel actions was strong.” Board Decision, 2022 WL 1144886, at *1. The IRB committee “recommended that Dr. Ginsberg’s scope of practice be amended 

to show that he could not serve in a clinical capacity on the 

[research] project . . . includ[ing] not having any access to 

patients or subject data.” J.A. 1184. The ORD Program 

Guide 1200.15 Section 4 states that “[r]esearch funds may 

only be awarded if the Principal Investigator (PI) and any 

Co-Principal Investigator (Co-PI) have employment status . . . of at least 25 hours per week (5/8ths),” J.A. 1173,

and Dr. Ginsberg was at a 2/8ths appointment after losing 

his clinical position. The Program Guide goes on to state 

that “[e]ligibility for VA research support remains in effect . . . until there is a change in investigator’s status,” 

J.A. 1174, which was the case for Dr. Ginsberg. As noted 

above, we view the IRB committee’s recommendation and 

the ORD Program Guide as strong evidence in support of 

the VA’s personnel actions.

With respect to the second Carr factor, substantial evidence supports the Board’s finding that “any motive to retaliate, if it existed here, was minimal.” Board Decision, 

2022 WL 1144886, at *2. As the Board acknowledged,

Dr. Omura and Dr. Haddock were both agency officials 

who were aware of the protected activity and were 

Case: 22-1900 Document: 46 Page: 6 Filed: 10/31/2023
GINSBERG v. DVA 7

responsible for several of the personnel actions, and thus, 

a motive to retaliate may have existed. On appeal, Dr. 

Ginsberg points to evidence he deems to be indicative of a 

retaliatory motive and animus on behalf of Drs. Omura and 

Haddock. See, e.g., Appellant’s Br. at 39–41. With respect 

to the motivations of Dr. Omura, we have no basis to credit 

Dr. Ginsberg’s contentions that the Board failed to consider 

all the pertinent evidence presented to it or that the Board 

was required to give Dr. Ginsberg’s preferred evidence 

more weight. As to Dr. Haddock, Dr. Ginsberg points to 

“an ethics complaint” Dr. Ginsberg had filed against Dr. 

Haddock, but Dr. Ginsberg did not claim (nor did the Board 

find) that this complaint was a protected activity. 

Dr. Omura and Dr. Haddock simply followed the recommendations of the IRB and the ORD, and there is no indication the members of the IRB were even aware of Dr. 

Ginsberg’s protected speech or activities. Initial Board Decision, 2021 WL 2894670; J.A. 1224–25. As the Board further noted, “other agency employees, such as an [ORD] 

employee . . . appear to have been involved in the personnel 

actions, but there is no evidence that they were aware of 

[Dr. Ginsberg’s] protected disclosure or protected activity.” 

Board Decision, 2022 WL 1144886, at *2 n.2. 

The Board found the third Carr factor neutral. The VA 

“failed to present evidence of nonwhistleblower comparator 

employees,” asserting that there were no comparator employees. Board Decision, 2022 WL 1144886, at *2 (citation 

omitted). As the Board acknowledged, we stated in 

Whitmore that “the absence of any evidence concerning 

Carr factor three may well cause the agency to fail to prove 

its case overall.” Whitmore v. Dep’t. of Labor, 680 F.3d 

1353 (Fed. Cir. 2012). But here, the agency presented testimony that “there have not been any individuals with suspended clinical privileges who are/were allowed to be a PI 

or Co-PI and access patients and [personal health information] data for the research project.” E.g., J.A. 1206, 

1210. Further, Dr. Ginsberg did not dispute the VA’s 

Case: 22-1900 Document: 46 Page: 7 Filed: 10/31/2023
8 GINSBERG v. DVA

assertion that there were “no similarly situated doctors 

who lost their clinical privileges and their Veterans Affairs 

(VA) appointments.” Board Decision, 2022 WL 1144886, 

at *2. Thus, we conclude that the Board’s finding that this 

factor is neutral is reasonable.

On appeal, Dr. Ginsberg argues that the agency’s view 

of comparator employees was too narrow. As an initial 

matter, we have reviewed Dr. Ginsberg’s briefing before 

the Board. It appears that Dr. Ginsberg never raised this 

argument and thus, it is forfeited. Kachanis v. Dep’t of 

Treasury, 212 F.3d 1289, 1293 (Fed. Cir. 2000) (“This court 

has long held that appellants may not raise issues on appeal for the first time.”). Even if we were to agree with 

Dr. Ginsberg’s argument as to this factor, “the agency need 

not prove every factor weighs in its favor, [and] the absence 

of evidence related to Carr factor three is not fatal to the 

agency.” Rickel v. Dep’t of the Navy, 31 F.4th 1358, 1366 

(Fed. Cir. 2022); Whitmore, 680 F.3d at 1374 (explaining 

that “Carr does not impose an affirmative burden on the 

agency to produce evidence” and show that each Carr factor 

weighs “individually in the agency’s favor”). Here, when 

“considering the evidence in the aggregate,” including the 

strength of the government’s evidence for Carr factors one

and two, the Board’s conclusion that the VA met its clear 

and convincing burden is supported by substantial evidence. See Robinson v. Dep’t of Veterans Affs., 923 F.3d 

1004, 1020 (Fed. Cir. 2019).

We have considered Dr. Ginsberg’s remaining arguments and find them unpersuasive.

CONCLUSION

For the foregoing reasons, we affirm the decision of the 

Board.

AFFIRMED

Case: 22-1900 Document: 46 Page: 8 Filed: 10/31/2023